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ABSTRAK
Karsinoma tiroid biasanya didiagnoskan berdasarkan kriteria morfologi tertentu. 
Dalam sesetengah kes, diagnosis yang tepat mungkin sukar apabila ciri-ciri 
morfologi adalah tidak ketara. Kajian ini menilai kegunaan Hector Battifora 
Mesothelial-1 (HBME-1) sebagai penanda immunohistokimia untuk membezakan 
tisu tiroid barah dengan bukan barah dan untuk membandingkan ekspresi HBME-1 
dalam pelbagai jenis tisu tiroid. Sensitiviti dan spesifisiti HBME-1 sebagai penanda 
khusus untuk karsinoma tiroid juga dikaji. Sejumlah 54 kes barah dan 54 kes bukan 
barah tiroid yang didiagnos di Pusat Perubatan Universiti Kebangsaan Malaysia 
untuk tempoh tujuh tahun telah dikumpul. Semua kes diwarnai dengan HBME-1 
dan dinilai oleh tiga pemerhati bebas. Kes-kes tersebut diberi skor berdasarkan 
nisbah pewarnaan dan dinilai sebagai skor 0 (kurang daripada 10%), 1+ (10-25%), 
2+ (26-50%) atau 3+ (lebih daripada 50%). Di samping itu, perkaitan antara skor 
bagi kes barah dengan peringkat patologi tumor juga dikaji. HBME-1 menunjukkan 
ungkapan pewarnaan yang lebih signifikan dalam kes barah berbanding bukan 
barah (P<0.001) dengan karsinoma tiroid papilari menunjukkan ungkapan tertinggi 
di kalangan kes karsinoma (87.1%). Kes bukan barah kebanyakannya adalah negatif 
(96%), kecuali dua kes adenoma folikular yang menunjukkan skor 1+. HBME-1 
mempunyai sensitiviti sebanyak 57% dan spesifisiti setinggi 96% bagi karsinoma 
tiroid. Tiada perkaitan antara ekspresi HBME-1 dengan peringkat patologi tumor 
berdasarkan klasifikasi TNM (pT). Kesimpulannya, HBME-1 berkemungkinan boleh 
menjadi penanda yang berguna dalam membezakan kes tiroid barah daripada 
bukan barah, terutamanya dalam kes-kes karsinoma tiroid papilari.
Kata kunci: adenoma folikular, antigen HBME-1, karsinoma tiroid papilari, tiroid
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ABSTRACT
Thyroid carcinomas are classically diagnosed based on specific morphological 
criteria. In some cases, a definitive diagnosis may be difficult when morphological 
features are equivocal. This study evaluated the utility of Hector Battifora 
Mesothelial-1 (HBME-1) as an immunohistochemical marker to differentiate 
malignant from benign thyroid lesions and to compare its expression in different 
types of thyroid lesions. The sensitivity and specificity of HBME-1 as a specific 
marker for thyroid carcinoma were also studied. A total of 54 malignant and 54 
benign thyroid cases diagnosed were collected in Universiti Kebangsaan Malaysia 
Medical Centre for a period of seven years. All cases were stained with HBME-1 
and evaluated by three independent observers. The cases were scored based on the 
proportion of staining and graded as 0 (less than 10%), 1+ (10-25%), 2+ (26-50%) or 
3+ (more than 50%). In addition, the score of malignant cases was correlated with 
their pathological tumour stage. HBME-1 showed significantly higher expression in 
malignant compared to benign lesions (P<0.001) with papillary thyroid carcinoma 
(PTC) showed the highest expression among the carcinoma cases (87.1%). Benign 
lesions were mostly negative (96%), except for two follicular adenoma cases having 
focal positivity. HBME-1 had a sensitivity of 57% and specificity of 96% in thyroid 
carcinoma. There was no correlation between HBME-1 expression and TNM 
primary tumour stage (pT). HBME-1 might be a useful marker in distinguishing 
malignant from benign thyroid lesions, especially in PTC cases. 
Keywords: follicular adenoma, HBME-1 antigen, papillary thyroid carcinoma, thyroid
and the incidence rate among females 
is three times higher than males (Bray 
et al. 2018). In Malaysia, thyroid cancer 
was ranked seventeenth among males 
and ninth among females (Azizah 
et al. 2016). Solitary thyroid nodule 
was the chief mode of presentation 
of thyroid cancer followed by a 
generalised thyroid enlargement, either 
multinodular or diffused (Abdullah 
2002; Sherma 2003). 
 Thyroid cancers constitute a few 
different histologic subgroups based 
on specific morphological features. 
The commonest subgroups are 
follicular carcinoma (FC), papillary 
INTRODUCTION
Thyroid follicular lesions denote 
the presence of either benign or 
malignant solid nodules, multinodular 
goitre, Graves’ disease or thyroiditis 
(Alshenawy 2014). Most of the thyroid 
lesions are benign. Nonetheless, 
cancer of the thyroid is the commonest 
malignancy of the endocrine system. 
There is a drastic increase in the 
worldwide incidence of thyroid cancer 
from 298,000 new reported cases in 
2012 to 567,233 cases in 2018 (Bray et 
al. 2018; Ferlay et al. 2015). Globally, it 
was ranked ninth place for incidence, 
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thyroid carcinoma (PTC), medullary 
carcinoma (MC), poorly-differentiated 
carcinoma and anaplastic carcinoma. 
A recent study from USA Surveillance, 
Epidemiology and End Results 
database carried out on 59,892 
thyroid cancer patients showed that 
PTC was the commonest type of 
thyroid carcinoma (92.2%). The next 
commonest is FC (5.8%), followed by 
MC (1.9%) and anaplastic carcinoma 
(0.7%) (Shi et al. 2018). PTC is further 
divided into variants, which include 
classic, follicular, tall cell, clear 
cell and other variants. The classic 
variant of PTC is the most common, 
followed by follicular variant (Nosé 
2018). Follicular variant PTC can 
be difficult to distinguish with other 
thyroid lesions with a follicular pattern, 
such as follicular adenoma and FC 
due to overlapping histomorphology 
(Erdogan-Durmus et al. 2016; Zargari 
& Mokhtari 2019). 
 Thyroid nodules are generally 
diagnosed by histopathology 
evaluation using haematoxylin and 
eosin (H&E) stained sections. In 
most cases, the diagnoses are quite 
straightforward. Sometimes, the 
pathologists may encounter lesions that 
exhibit equivocal features, making it 
difficult to distinguish between benign 
and malignant lesions (Haiyan & Fan 
2015). For instance, even though the 
diagnostic criteria for PTC and FC are 
clearly outlined in the World Health 
Organisation (WHO) Classifications 
and other textbooks, the discrepancies 
in the diagnosis of thyroid follicular 
lesions are very well documented, 
even among experienced pathologists 
(Franc et al. 2003; Lloyd et al. 2004). The 
diagnostic dilemma in distinguishing 
follicular variant PTC with FC or 
follicular adenoma may arise due to 
the presence of focal nuclear features 
of PTC, or interpretation of capsular or 
vascular invasion (Zargari & Mokhtari 
2019). 
 Thus, the efforts to identify 
biomarkers in differentiating thyroid 
lesions are of great importance. 
Recently, many studies were 
conducted not only to look for useful 
immunohistochemical markers that 
are able to differentiate benign from 
malignant thyroid lesions but also 
differentiating variants in thyroid 
carcinomas (Alshenawy 2014; Cheung 
et al. 2001; Haiyan & Fan 2015). The 
panel of markers has been proposed; 
however, to date, no single marker has 
been established as a sensitive and 
specific marker in differentiating the 
thyroid lesions. Among the previously 
studied biomarkers, Hector Battifora 
Mesothelial-1 (HBME-1) is noted to 
be potentially helpful in diagnosing 
thyroid lesions. 
 HBME-1 is a membrane antigen 
that is seen within normal tracheal 
epithelia, the microvilli of mesothelial 
cells as well as in some carcinomas 
of the pancreas, lung and breast (Sack 
et al. 1997). Initially, HBME-1 was 
recognized as a mesothelial marker. 
It was also seen to be expressed in 
some normal and neoplastic tissues 
including thyroid carcinoma. Few 
studies were carried out to explore this 
marker’s expression in various thyroid 
lesions, especially in malignancy. 
Miettinen and Kärkkäinen described 
a strong and dispersed HBME-1 
expression in PTC and FC cases, while 
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benign lesions and normal thyroid 
parenchyma were either negative or 
showed only focal and weak positivity 
(Miettinen & Karkkainen 1996). Mase 
et al. reported that HBME-1 showed 
84.6% positivity in FC and 97.2% in 
PTC in 205 specimens excised (Mase 
et al. 2003). Another meta-analysis 
conducted showed that increased 
expression of HBME-1 in a thyroid 
nodule is suggestive of malignancy, 
and this is particularly true for PTC. 
This analysis also showed HBME-
1 sensitivity of 78.8% for thyroid 
malignancy, 87.3% for PTC and 65.2% 
for FC, with a specificity of 82.1% 
(Haiyan & Fan 2015).
 The purpose of this study is to 
determine the utility of HBME-1 in 
distinguishing benign and malignant 
thyroid lesions and to support 
the use of HBME-1 as a routine 
immunohistochemistry panel to aid 
the diagnosis of thyroid neoplasms.
MATERIALS AND METHODS
Tissue Specimens
The study approval was obtained from 
the Ethical Committee of Universiti 
Kebangsaan Malaysia (Ref No. UKM 
FPR.4/244/FF-2017-101). Altogether 
108 thyroidectomy specimens were 
included in the study, which comprised 
54 malignant and 54 benign thyroid 
lesions. The malignant lesions include 
PTC (31 cases), FC (11 cases), MC 
(seven cases), poorly differentiated 
carcinoma (one case) and anaplastic 
carcinoma (four cases). The benign 
lesions include hyperplastic nodule/
goiter (28 cases), follicular adenoma 
(14 cases), lymphocytic thyroiditis (11 
cases) and a hyalinising trabecular 
tumour. These cases were all diagnosed 
at the Universiti Kebangsaan Malaysia 
Medical Centre within a period of 
seven years. The classification of the 
malignant cases was based on the WHO 
Classification Tumours of Endocrine 
Organs (fourth edition). All cases 
were reviewed by three independent 
observers, i.e., one trainee and two 
pathologists under light microscopy. 
Subsequently, the most representative 
section and its corresponding paraffin 
block were selected for each case for 
immunohistochemical staining with 
HBME-1.
Immunohistochemical Staining 
Method
Monoclonal Mouse Anti-Human 
Mesothelial Cell, clone HBME-1 (Code 
M3505, Dako Denmark) was used as 
the primary antibody, at a dilution of 
1:100. The positive control used was a 
mesothelioma tissue.
 The immunohistochemistry was 
carried out on formalin-fixed paraffin 
embedded (FFPE) tissue sections 
using the protocol from EnVision™ 
FLEX+, Mouse, High pH (Code No. 
K8012, Dako Denmark). The primary 
antibody dilution was performed to 
achieve optimal concentration using 
Antibody Diluent, Dako REALTM (Code 
No. S2022, Dako Denmark). The 
washing steps were done between 
each reagent, using EnVisionTM FLEX 
Wash Buffer 20x (Code No. DM831, 
Dako Denmark). The 1X DAB-
containing Substrate Working Solution 
was prepared by diluting the 50X 
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concentrated EnVisionTM FLEX DAB+ 
Chromogen (Code No. DM827, Dako 
Denmark) with EnvisionTM FLEX TM 
Substrate Buffer (Code No. DM823, 
Dako Denmark).
 The FFPE tissue was sectioned to 
about 3 μm thickness and mounted 
on an adhesive glass slide, then it was 
left to be air-dried overnight at room 
temperature. Subsequently, the slides 
were incubated on a hot plate (60˚C) 
for an hour. An initial deparaffinization 
and pre-treatment step were then 
performed in the Decloaking 
Chamber™ NxGen (Ref. No: DC2012-
220V, Biocare Medical California) using 
the EnVision™ FLEX Target Retrieval 
Solution, High pH (Code No. DM828, 
Dako Denmark), with the temperature 
of 110˚C for 30 minutes. Later, the slides 
were cooled at room temperature for 
30 minutes and subsequently rinsed 
with running tap water for three 
minutes. Subsequently, the slides 
were incubated with EnVisionTM FLEX 
Peroxidase-Blocking Reagent (Code 
No. DM821, Dako Denmark) for five 
minutes. This is followed by another 
washing step.
 The next step was incubation with 
primary antibody for 30 minutes 
at room temperature, followed by 
incubation with EnVisionTM FLEX/HRP 
(Code No. DM822, Dako Denmark) 
for 20 minutes. Then, the slides were 
incubated with 1X DAB-containing 
Substrate Working Solution for 10 
mins. Following that, the tissues were 
counterstained with Hematoxylin 2 
(REF 7231, Thermo Scientific, USA) for 
15 seconds, followed by dehydration 
steps using increasing alcohol solutions 
(80%, 90%, 100% and 100%) and 
two times Xylene. Finally, the slides 
were mounted using DPX mounting 
medium (Cat. No.: 100579, Merck 
Millipore, Germany).
HBME-1 Immunohistochemical 
Staining Evaluation
The staining was evaluated by three 
observers independently and they 
were blinded from the initial diagnosis. 
The consensus of the majority (2/3 or 
3/3) was taken as the final result. The 
cases were considered as positive 
if immunoreactivity was seen at the 
cell cytoplasm and/or cytoplasmic 
membrane of the lesional cells. Each 
case was semiquantitatively evaluated 
for the proportion score on a 4-point 
scale as either 0 (less than 10% 
positivity), 1+ (10-25% positivity), 2+ 
(26-50% positivity) and 3+ (more than 
50 % positivity). This scoring system 
was based on a previously published 
study (Alshenawy 2014). In cases where 
there were staining of the colloid but no 
staining seen on the thyroid epithelial 
cells, it was considered negative.
Statistical Analysis
The data obtained were analysed using 
the “Statistical Package for the Social 
Sciences (SPSS) for Windows” software 
(version 20.0) (IBM Corp. Armonk, 
NY, USA). The Chi-Square test was 
used to assess the null hypothesis. 
The p-value of <0.05 was considered 
to be statistically significant. The 
categorical data were presented in 
frequency. The sensitivity, specificity, 
positive predictive value and negative 
predictive value were assessed in both 
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benign and malignant thyroid lesions.
RESULTS
Epidemiology and 
Clinicopathological Data
Altogether, 54 malignant and 54 benign 
cases were included in the study. Both 
benign and malignant lesions showed 
female predilection. The incidence of 
thyroid cancer was the highest among 
the Malay ethnicity (59.2%), followed 
by Chinese (22.2%) and Indians 
(11.1%). The extrathyroidal extension 
was noted in 10/54 (18.5%) malignant 
cases, and 18/54 (33.3%) cases showed 
nodal metastasis. Distant metastasis 
was observed in three malignant cases. 
Baseline demographic characteristics 
of both benign and malignant groups 
are shown in Table 1. 
HBME-1 Expression
HBME-1 expression was significantly 
Variables Benign cases Malignant cases
Mean age (SD) 45.8 (14.7) 49.17 (14.17)
Gender      
   Male                                                
   Female
12 (22.2%)
42 (77.8%)
20 (37%)
34 (63%)
Ethnicity
    Malay
    Chinese
    Indian
    Others 
32 (59.3%)
13 (24.1%)
5 (9.3%)
4 (7.4%)
32 (59.3%)
12 (22.2%)
6 (11.1%)
4 (7.4%)
Size of lesion   
    ≤ 2cm
    2- 4 cm
    > 4cm
    Not available
1 (1.9%)
10 (18.5%)
39 (66.7%)
4 (7.4%)
13 (24.1%)
20 (37.0%)
18 (33.3%)
3 (5.6%)
Extrathyroidal extension
    Present
    Absent              
-
-
10 (18.5%)
44 (81.5%)
Nodal metastasis
    Present
    Absent
-
-
18 (33.3%)
36 (66.7%)
Distant metastasis
    Present
    Absent
-
-
3 (5.6%)
51 (94.4%)
Table 1: Demographics and clinicopathological data of study groups.
HBME-1 Pattern Malignant Benign p-value
0 23 (42.6%) 52 (96.3%) < 0.001
1+ 8 (14.8%) 2 (3.7 %)
2+ 2 (3.7%) 0 (0%)
3+ 21 (38.9%) 0 (0%)
Table 2: Comparison of HBME-1 staining pattern between malignant and benign cases
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higher in malignant compared to 
benign lesions (P<0.001) (Table 
2). Positive staining was observed 
predominantly in malignant cases 
(31/54, 57.4%), while only two benign 
cases were positive (2/54, 3.7%). Out 
of the 31 positive cases, 21 cases 
(38.9%) showed score 3+, while none 
of the benign lesions showed more 
than 50% positivity. The two benign 
cases showed only score 1+. The rest 
of the benign lesions (52/54, 96.3%) 
were negative (Table 2). The positive 
malignant cases mostly demonstrated 
score 2+ and 3+ (23/31), while the 
benign lesions were either negative 
(52/54, 96.3%) or showed score 1+ 
(2/54, 3.7%).
 Further analysis of the 31 malignant 
cases revealed the highest HBME-
1 positivity in PTC (27/31, 87.1%), 
followed by anaplastic carcinoma 
(1/4, 25%), follicular carcinoma (2/11, 
18.2%) and medullary carcinoma (1/7, 
14.3%). The PTC cases mostly showed 
the score 3+ (20/31, 64.5%). Both 
medullary and anaplastic carcinoma 
scored only 1+. The only case of poorly 
differentiated carcinoma included in 
this study was negative (Table 3).
Sensitivity, Specificity, Positive 
Predictive Value (PPV) and Negative 
Predictive Value (NPV) of HBME-1 
in Malignant Thyroid Neoplasms
The analysis showed that HBME-1 had 
a sensitivity of 57.4% and specificity 
of 96.3%, with a high PPV (93.9%) in 
distinguishing malignant from benign 
thyroid lesions. The NPV was 69.3%.
Correlation of HBME-1 Expression 
with Pathological Tumour Stage 
(pT), Nodal and Distant Metastasis
Further analysis showed no significant 
HBME-1 
staining 
pattern
Papillary
carcinoma 
Follicular 
carcinoma
Medullary 
carcinoma
Poorly 
differentiated 
carcinoma
Anaplastic
carcinoma
Total
0 4 (12.9%) 9 (81.8%) 6 (85.7%) 1 (100%) 3 (75%) 23
1+ 5 (16.1%) 1 (9.1%) 1 (14.3%) 0 (0%) 1 (25%) 8
2+ 2 (6.5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2
3+ 20 (64.5%) 1 (9.1%) 0 (0%) 0 (0%) 0 (0%) 21
Total 31(100.0%) 11(100.0%) 7(100.0%) 1(100.0%) 4(100.0%) 54
Table 3: HBME-1 staining pattern in different subtypes of thyroid malignancies.
HBME-1 Pattern pT1 pT2 pT3 pT4 p-value
0 5 (33.3) 7 (53.8%) 8 (36.4%) 3 (75.0%) 0.462
1+ 2 (13.3%) 0 (0.0%) 5 (22.7%) 1 (25.0%)
2+ 0 (0.0%) 1 (7.7%) 1 (4.5%) 0 (0.0%)
3+ 8 (53.3%) 5 (38.5%) 8 (36.4%) 0 (0.0%)
Table 4: Correlation between HBME-1 staining patterns in malignant cases with their 
pathological tumour stage (pT)
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correlation between HBME-1 
expression and the pathological 
TNM primary tumour stage (P=0.462) 
(Table 4). A similar finding was shown 
when only PTC cases were analysed 
according to their pathological tumour 
stage (P=0.08) (Table 5). Further 
analysis also indicated no correlation 
between HBME-1 expression with 
nodal status (P=0.91) and distant 
metastasis (P=0.79) (Table 6).
DISCUSSION
The diagnosis of thyroid neoplasms 
depends mainly on their specific 
morphological features, which at times 
can be challenging. Studies have shown 
intra-observer and inter-observer 
variability among the pathologists 
in diagnosing thyroid neoplasms, 
especially in follicular variant PTC and 
the FC (Franc et al. 2003; Lloyd et al. 
2004). Recent advances in molecular 
technologies have enhanced our 
awareness and understanding of 
the genetic basis of many thyroid 
tumours. However, molecular testing 
for classification of thyroid neoplasm 
is impossible, impractical and rather 
costly. Thus, the diagnosis of thyroid 
lesions still depends mainly on 
morphological classification. 
 PTC is the most common subtypes 
of thyroid cancer and consisted 
80% of all thyroid carcinoma (Lloyd 
et al. 2017; Nosé 2018). Local data 
published in 2002 by Abdullah 
showed a slightly different percentage, 
i.e., PTC (69%), FC (21%), MC (7%) and 
other malignancies such as anaplastic 
carcinoma and Hurtle cell carcinoma 
(3%) (Abdullah 2002). Another local 
published data also reported PTC as 
the most common type for thyroid 
carcinoma (76.6%) (Nor Hayati et 
al. 2009). A review article on thyroid 
malignancy of hospital-based studies 
HBME-1 Pattern pT1 pT2 pT3 pT4 p-value
0 0 (0.0%) 0 (0.0%) 4 (23.5%) 0 (0.0%) 0.08
1+ 0 (0.0%) 0 (0.0%) 4 (23.5%) 1 (100.0%)
2+ 0 (0.0%) 1 (20.0%) 1 (5.9%) 0 (0.0%)
3+ 8 (100.0%) 4 (80.0%) 8 (47.1%) 0 (0.0%) 
Table 5: Correlation between HBME-1 staining pattern in papillary thyroid carcinoma 
with their pathological tumour stage (pT)
HBME-1 Pattern
Nodal Metastasis Distant Metastasis
Present Absent p-value Present Absent p-value
0 8 (44.4%) 15 (41.7%) 0.91 2 (66.7%) 21 (41.2%) 0.79
1+ 3 (16.7%) 5 (13.9%) 0 (0.0%) 8 (15.7%)
2+ 1 (5.65) 1 (2.8%) 0 (0.0%) 2 (3.9%)
3+ 6 (33.3%) 15 (41.7%) 1 (33.3%) 20 (39.2%)
Table 6: Correlation between HBME-1 staining pattern in malignant cases with their 
nodal and distant metastasis
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in Malaysia and Myanmar also showed 
PTC as the commonest histological 
type of thyroid carcinoma ranging from 
57.5-76.6% (Htwe 2012). In our study, 
PTC comprised 57.4% of all thyroid 
cancers. 
 We analysed 108 cases of thyroid 
lesions and the demographics show a 
slightly older median age at diagnosis 
of malignant neoplasms (49.17 years) 
compared to benign lesions (45.8 
years). However, our local cancer 
registry showed that the highest age-
specific incidence rate for thyroid 
malignancies for both males and 
females was 65 years (Azizah et al. 
2016). In this study, the female to male 
ratio was 1.7:1 compared to 3.3:1 for 
global incidence and 3.13:1 for national 
incidence (Azizah et al. 2016; Bray et 
al. 2018).
 Many immunohistochemical 
markers were studied previously to 
assist in the diagnosis of malignant 
thyroid neoplasms. HBME-1 is one of 
the promising immunomarkers that 
have been analysed (Alshenawy 2014; 
Cochand-Priollet et al. 2011; Nga et 
al. 2008). HBME-1 is a membrane 
antigen seen in the mesothelial cells, 
normal tracheal epithelium and in the 
carcinoma of the lung, pancreas and 
breast (Bateman et al. 1997; Sack et al. 
1997). 
 Previously published studies have 
shown that HBME-1 expression is 
generally increased in malignant 
thyroid lesions (Dunderovic et al. 
2015; Ohta et al. 2015). In this study, 
the percentage of HBME-1 positivity 
was highest in PTC (87.1%) compared 
to other tumour subtypes. This finding 
coincided with other published studies 
that reported a high percentage of 
positivity in PTC, ranging from 55-
97% (Alshenawy 2014; Cheung et al. 
2001; Dunderovic et al. 2015; Haiyan 
& Fan 2015). We postulated that higher 
HBME-1 expression seen in PTC might 
be related to the BRAFV600E point 
mutation, as this somatic mutation 
was found in up to 90% of PTC cases 
(Nosé 2018). However, further studies 
are needed to clarify this hypothesis.
 Normal or benign thyroid lesions 
were generally negative for HBME-
1, as demonstrated by earlier studies 
(Alshenawy 2014; Erdogan-Durmus et 
al. 2016). This study is in agreement 
with those studies, as there is a high 
percentage of negativity for benign 
lesions (96.3%, 52/54). However, 1+ 
staining pattern was only observed 
in two out of 14 cases of follicular 
adenoma (3.7%). This was also seen in 
another study that showed weak and 
focal expression of HBME-1 in follicular 
adenoma (Haiyan & Fan 2015). From 
these findings, we can presume that 
when HBME-1 is negative or showing 
focal or weak positivity, the diagnosis 
of benign lesions is favoured. When 
a benign lesion, such as follicular 
adenoma, shows strong or moderate 
HBME-1 expression, a more thorough 
evaluation of the nuclear features to 
exclude PTC or presence of capsular 
or vascular invasion to exclude FC 
must be done. A study done by Mase 
et al. (2003) reported a strong HBME-1 
expression in follicular adenoma cases 
and surprisingly, some of those cases 
were re-diagnosed as FC and PTC after 
the thorough histological examination 
was conducted. 
 In terms of HBME-1 sensitivity and 
196
Med & Health Jun 2020;15(1): 187-197 Noor 'Ain M.N. et al.
specificity, Alshenawy (2014) reported 
the sensitivity and specificity of 80% 
and 84% respectively in distinguishing 
malignant from benign thyroid lesions. 
Another study showed 84% sensitivity 
and 98% specificity with a PPV of 98% 
and a NPV of 83% (Zargari & Mokhtari 
2019). However, our study only 
demonstrated a sensitivity of 57.4% 
and specificity of 96.3%, with PPV of 
93.6% and NPV of 69.3%. Of note, a 
marker with high specificity and PPV 
is needed for diagnostic purposes 
especially in malignant lesions. With 
the findings of high specificity and PPV 
for HBME-1 expression in malignant 
cases, we highly recommend this 
marker to be included as one of the 
immunohistochemical panels for 
distinguishing benign from malignant 
thyroid neoplasms.
 Our study found no correlation 
between HBME-1 expression and the 
clinical outcome (i.e. tumour stage, 
nodal status and distant metastasis). 
The result is comparable to a recent 
study published by Cho et al. (2018), 
which does not support the role of 
HBME-1 as a prognostic marker in 
thyroid lesions. 
CONCLUSION
Our study concluded that HBME-
1 might be a useful marker in 
distinguishing malignant from benign 
thyroid lesions, particularly for cases 
of PTC. When the morphological 
features are equivocal (between 
benign and malignant) and the 
HBME-1 is diffusely positive, then a 
malignancy should be considered. 
However, HBME-1 expression may 
not be so helpful in cases of other 
thyroid malignancies such as poorly 
differentiated carcinoma, anaplastic 
carcinoma and medullary carcinoma, 
as demonstrated in our study. On the 
contrary, negative HBME-1 staining 
strongly suggests a benign condition 
in a correct morphological setting. 
Our study also showed that HBME-
1 has high specificity and PPV in 
discriminating between benign and 
malignant thyroid lesions. 
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